Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000489809 | SCV000576493 | pathogenic | not provided | 2018-02-21 | criteria provided, single submitter | clinical testing | The c.4914_4917delCTCT variant in the NF1 gene has been reported previously in association with neurofibromatosis type 1 (Side et al., 1997; Uusitalo et al., 2014; Esposito et al., 2015). The deletion causes a frameshift starting with codon Lysine 1640, changes this amino acid to a Glycine residue and creates a premature Stop codon at position 36 of the new reading frame, denoted p.Lys1640GlyfsX36. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). In summary, we consider this variant to be pathogenic. |
Ambry Genetics | RCV000492080 | SCV000581248 | pathogenic | Hereditary cancer-predisposing syndrome | 2014-06-13 | criteria provided, single submitter | clinical testing | The c.4977_4980delCTCT(also known as c.4914delCTCT) pathogenic mutation, located in coding exon 37 of the NF1 gene, results from a deletion of 4 nucleotides between nucleotide positions 4977 and 4980, causing a translational frameshift with a predicted alternate stop codon (<span style="background-color: initial;">p.K1661Gfs*36)<span style="background-color: initial;">. This pathogenic mutation was first identified in a 10 month old child with NF1 and acute myeloid leukemia; the child inherited the mutation from his father, who also had NF1 (<span data-redactor="verified" style="background-color: initial;">Side L et al. N Engl J Med. 1997; 336(24):1713-20). In addition to the clinical data presented in the literature, s<span data-redactor="verified" style="background-color: initial;">ince frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294). |
Center for Human Genetics, |
RCV000660069 | SCV000782038 | pathogenic | Neurofibromatosis, type 1 | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000660069 | SCV001200736 | pathogenic | Neurofibromatosis, type 1 | 2023-12-31 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys1640Glyfs*36) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with neurofibromatosis, type 1 (PMID: 9180088, 24676424, 26478990). This variant is also known as 4914delCTCT. ClinVar contains an entry for this variant (Variation ID: 426127). For these reasons, this variant has been classified as Pathogenic. |
Genome- |
RCV000660069 | SCV002560095 | pathogenic | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
3billion | RCV000660069 | SCV002573159 | pathogenic | Neurofibromatosis, type 1 | 2022-09-01 | criteria provided, single submitter | clinical testing | The variant is not observed in the gnomAD v2.1.1 dataset. Frameshift variant is predicted to result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic with clinical assertions and evidence for the classification (ClinVar ID: VCV000426127 / PMID: 9180088). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. |
Neuberg Centre For Genomic Medicine, |
RCV000660069 | SCV004100507 | pathogenic | Neurofibromatosis, type 1 | criteria provided, single submitter | clinical testing | The frameshift deletion p.K1640Gfs*36 in NF1 (NM_000267.3) has been reported in affected individuals (Side et al., 1997; Uusitalo et al., 2014; Esposito et al., 2015). It has been submitted to ClinVar as Pathogenic.The p.K1640Gfs*36 variant is novel (not in any individuals) in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. This variant is predicted to cause loss of normal protein function through protein truncation. For these reasons, this variant has been classified as Pathogenic. |